# MDCX catalysts: Medicus Pharma Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mdcx/catalysts

> Medicus Pharma Ltd. (MDCX) has no upcoming catalysts in this calendar. The latest recorded is the SKNJCT-003 interim data readout, Q1 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MDCX?

Medicus Pharma Ltd. (MDCX) has no upcoming catalysts in this calendar. The latest recorded is the SKNJCT-003 interim data readout, Q1 2025. Press release filed with the SEC (EX-99): "Medicus is planning to initiate an interim data analysis in Q1 2025 and submit its findings to the United States Food and Drug Administration (FDA) as a part of a package seeking a Type C meeting with the FDA in Q2 2025." [Calendar and source filings](https://sec-api.dev/companies/mdcx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001062993-24-019855, https://www.sec.gov/Archives/edgar/data/1997296/000106299324019855/exhibit99-1.htm (retrieved 2026-11-12). Last confirmed 2024-12-02. Cite: https://sec-api.dev/companies/mdcx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Medicus Pharma Ltd. |
| Ticker | MDCX (Nasdaq) |
| SEC CIK | 1997296 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mdcx |

## Cash runway

Cash $5.0M as of 2026-09-30; quarterly burn $15.9M; about 0.9 months of runway at that rate (XBRL company facts, accession 0001062993-26-005803).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2023 | [Design FDA approval](https://sec-api.dev/pdufa/design) | MDCX |  | completed, approved | "In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1997296/000106299325017085/exhibit99-1.htm)) |
| Nov 2024 | [Design FDA approval](https://sec-api.dev/pdufa/design) | MDCX |  | completed, approved | "In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1997296/000106299325015700/exhibit99-1.htm)) |
| Q1 2025 | [SKNJCT-003 interim data readout](https://sec-api.dev/pdufa/sknjct-003) | MDCX |  | scheduled | "Medicus is planning to initiate an interim data analysis in Q1 2025 and submit its findings to the United States Food and Drug Administration (FDA) as a part of a package seeking a Type C meeting with the FDA in Q2 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1997296/000106299324019855/exhibit99-1.htm)) |

## Drugs

- [Design](https://sec-api.dev/pdufa/design): 
- [SKNJCT-003](https://sec-api.dev/pdufa/sknjct-003): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mdcx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MDCX catalysts: Medicus Pharma Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mdcx/catalysts

```bibtex
@misc{secapidev_companies_mdcx_catalysts_20261116,
  title        = {MDCX catalysts: Medicus Pharma Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mdcx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mdcx_catalysts_20261116","title":"MDCX catalysts: Medicus Pharma Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mdcx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
